SAN DIEGO, CA and COPENHAGEN, DK, November 13, 2002 - ACADIA Pharmaceuticalsannounced today the appointment of Paul S. Anderson, Ph.D., to its ScientificAdvisory Board. Dr. Anderson is one of the world's most highly respected medicalchemists and has nearly 40 years of experience in drug research. Most recently,Dr. Anderson held the position of Vice President, Drug Discovery at Bristol-MyersSquibb. Earlier in his career, he held the positions of Vice President of Chemistryat Merck Sharp and Dohme's West Point facility, and Senior Vice President ofChemical and Physical Sciences at DuPont Pharmaceuticals.
During his tenure with Merck, Dr. Anderson directed numerous highly successfuldrug discovery efforts including those leading to ZOCOR, the leading cholesterollowering agent, TRUSOPT, the first carbonic anhydrase inhibitor for topicaltreatment of glaucoma, and MK-801, one of the industry's most widely-studiedcentral nervous system experimental substances. More recently, he has directedextensive medicinal chemistry efforts at Merck and DuPont committed to discoveryof new chemotherapy for Aids. These efforts led to CRIXIVAN, an HIV proteaseinhibitor, and SUSTIVA, an HIV reverse transcriptase inhibitor.
Over the years, Dr. Anderson has served the American Chemical Society, theNational Institutes of Health, and the National Research Council in a varietyof senior positions, including President of the American Chemical Society in1997. He is also the recipient of numerous awards including the E.B. HershbergAward, the American Chemical Society Award in Industrial Chemistry, and the2002 Perkin Medal. Dr. Anderson has received honorary doctorates from the Universityof Vermont and the University of New Hampshire.
"We are very fortunate to be able to tap into Paul Anderson's unique competence,"said Mark R. Brann, Ph.D., President and Chief Scientific Officer at ACADIA."We have many exciting drug discovery programs that will benefit from hisextensive experience in pharmaceutical drug discovery and development. In additionto having our first two drug candidates entering clinical trials shortly, ACADIAhas several programs rapidly approaching development and we believe that Dr.Anderson's extensive experience will provide an optimal complement to ACADIA'sScientific Advisory Board."
"Dr. Anderson is not only one of the world's finest medicinal chemists,but also one of the few great drug discoverers. His experience will be invaluablefor ACADIA in our efforts to advance our drug discovery programs to the clinic,"said Uli Hacksell, Ph.D., Chief Executive officer at ACADIA.
ACADIA Pharmaceuticals is a drug discovery and development company that efficientlydiscovers small molecule drug candidates using its proprietary chemical-genomicsplatform. ACADIA has successfully applied its platform to generate a broad discoverypipeline that includes advanced programs directed at major diseases, includingParkinson's disease, psychosis, chronic pain, and glaucoma. ACADIA's corporateheadquarters as well as its genomics and biological research facilities arelocated in San Diego, California and its chemistry research facilities are locatedin Copenhagen, Denmark.
Contact:
ACADIA PharmaceuticalsMark R. Brann, President and CSO+1 858-558-2871
Europe:
Bo-Ragnar Tolf, Ph.D., VP of Chemistry and
Managing Director of ACADIA Pharmaceuticals A/S
+45 4329-3000